guardianactual
MuscleChemistry Registered Member
ACP-105 potent anabolic effects and possible necessary drug for a doomsday Nuclear event 
(Two sources on this compound)
Overview:
ACP-105, a novel non-steroidal SARM. ACP-105 is shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors. In addition, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models.
ACP-105 is a non-steroidal and selective androgen receptor agonist. ACP-105 is part of a class of molecules referred to as selective androgen receptor modulators (SARMs). SARMs may advance the standard of treatment for a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer side effects as compared to current treatments based on testosterone replacement. ACP-105 has exhibited promising pharmacological properties and a favorable safety profile in preclinical testing.

Dosage
Note; dosage information is only for scientific reference purposes. SARMs Central, does not condone the human consumption or use of this substance outside of a controlled scientific environment (i.e. a lab).
As a general guideline we would suggest ‘testing’ a new SARM at about 10-15 mg per day and see how your body reacts. If you don’t experience any adverse effects or results you can steadily start increasing the dosage by 10mg per day.*
Extra info
LG121071
Just to make things clear: LG121071 [structural formula shown on the right], developed by Ligand Pharmaceuticals, is still difficult for athletes to get hold of, but doping hunters at the German Sport University Cologne have already developed a doping test for it for WADA.*[Eur J Mass Spectrom (Chichester, Eng). 2015;21(1):27-36.]*At the time of writing the test had not yet been introduced, but by the time you read this, the situation may have changed.
In 1999 researchers at Ligand Pharmaceuticals published a study*[J Med Chem. 1999 Jan 28;42(2):210-2.]*in which they reported that LG121071 attaches just as well as DHT to the androgen receptor.
In the table below 1b is DHT, 2 is fluoxymesterone [the active substance in Halotestin] and 8 is LG121071.

LG121071 works when taken orally, but daily doses of several tens of milligrams are probably needed for humans. We have not come across studies that describe the effects of LG121071 on muscles and the prostate, but there are likely to be effects. The elite doping hunters at WADA are not developing the doping test for nothing of course.
ACP-105
ACP-105 [structural formula on the right] is produced in the laboratories of the Swedish company Acadia Pharmaceuticals. As far as we know, ACP-105 is not yet available in online stores where chemical athletes do their shopping, and a doping test has already been developed for it.*[Eur J Mass Spectrom (Chichester, Eng). 2014;20(1):73-83.]
ACP-105 was first mentioned in the scientific literature in 2009.*[J Med Chem. 2009 Nov 26;52(22):7186-91.]*This study showed that a relatively low concentration of ACP-105 attaches itself to the androgen receptor better than DHT does. In the figures below, taken from the publication we just mentioned, 1 represents ACP-105.

ACP-105 can be taken orally and may be an effective SARM, according to the results of an animal study that the researchers performed. "The principal finding from this study was that 1 [ACP-105] produced a robust anabolic effect on the levator ani muscle (67% reversal of ORX-induced atrophy at 1 (mg/kg)/day) while having lesser androgenic effects on prostate (21% reversal; T, 48%)", they wrote.
The*human equivalent*of the dosage mentioned, for a man weighing 80 kg, would be about 11 mg per day.
From animal studies it seems that ACP-105 may offer protection against the effects of nuclear radiation.*[Brain Res. 2011 Mar 24;1381:134-40.]
(Two sources on this compound)
Overview:
ACP-105, a novel non-steroidal SARM. ACP-105 is shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors. In addition, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models.
ACP-105 is a non-steroidal and selective androgen receptor agonist. ACP-105 is part of a class of molecules referred to as selective androgen receptor modulators (SARMs). SARMs may advance the standard of treatment for a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer side effects as compared to current treatments based on testosterone replacement. ACP-105 has exhibited promising pharmacological properties and a favorable safety profile in preclinical testing.

Dosage
Note; dosage information is only for scientific reference purposes. SARMs Central, does not condone the human consumption or use of this substance outside of a controlled scientific environment (i.e. a lab).
As a general guideline we would suggest ‘testing’ a new SARM at about 10-15 mg per day and see how your body reacts. If you don’t experience any adverse effects or results you can steadily start increasing the dosage by 10mg per day.*
Extra info
LG121071
Just to make things clear: LG121071 [structural formula shown on the right], developed by Ligand Pharmaceuticals, is still difficult for athletes to get hold of, but doping hunters at the German Sport University Cologne have already developed a doping test for it for WADA.*[Eur J Mass Spectrom (Chichester, Eng). 2015;21(1):27-36.]*At the time of writing the test had not yet been introduced, but by the time you read this, the situation may have changed.
In 1999 researchers at Ligand Pharmaceuticals published a study*[J Med Chem. 1999 Jan 28;42(2):210-2.]*in which they reported that LG121071 attaches just as well as DHT to the androgen receptor.
In the table below 1b is DHT, 2 is fluoxymesterone [the active substance in Halotestin] and 8 is LG121071.

LG121071 works when taken orally, but daily doses of several tens of milligrams are probably needed for humans. We have not come across studies that describe the effects of LG121071 on muscles and the prostate, but there are likely to be effects. The elite doping hunters at WADA are not developing the doping test for nothing of course.
ACP-105
ACP-105 [structural formula on the right] is produced in the laboratories of the Swedish company Acadia Pharmaceuticals. As far as we know, ACP-105 is not yet available in online stores where chemical athletes do their shopping, and a doping test has already been developed for it.*[Eur J Mass Spectrom (Chichester, Eng). 2014;20(1):73-83.]
ACP-105 was first mentioned in the scientific literature in 2009.*[J Med Chem. 2009 Nov 26;52(22):7186-91.]*This study showed that a relatively low concentration of ACP-105 attaches itself to the androgen receptor better than DHT does. In the figures below, taken from the publication we just mentioned, 1 represents ACP-105.

ACP-105 can be taken orally and may be an effective SARM, according to the results of an animal study that the researchers performed. "The principal finding from this study was that 1 [ACP-105] produced a robust anabolic effect on the levator ani muscle (67% reversal of ORX-induced atrophy at 1 (mg/kg)/day) while having lesser androgenic effects on prostate (21% reversal; T, 48%)", they wrote.
The*human equivalent*of the dosage mentioned, for a man weighing 80 kg, would be about 11 mg per day.
From animal studies it seems that ACP-105 may offer protection against the effects of nuclear radiation.*[Brain Res. 2011 Mar 24;1381:134-40.]
